Kevin Young, MD
Cardiovascular Disease · Nashville, TNNPI 1386608768
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,920 of the $14,057 with a category attached, or 63.5%. Esperion Therapeutics, Inc. accounts for 66.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $7,410 and has fallen 81.5% since, to $1,370 in 2025.
Across 229 payments — averaging $61.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$9K
- Boston Scientific$875
- Novartis$602
- Amgen$566
- Cleerly, Inc.$487
- Heartflow, Inc.$401
- plus $2K from 15 others
Across 7 payments — averaging $16,400 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Heartflow, Inc.$115K
What the payments were for
- Speaking & faculty fees$8,92063%
- Travel & lodging$1021%
- Food & beverage$4,97035%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 13 | $9,327 |
| Boston Scientific | 28 | $875 |
| Novartis | 34 | $602 |
| Amgen | 29 | $566 |
| Cleerly, Inc. | 4 | $487 |
| Heartflow, Inc. | 11 | $401 |
| E.r. Squibb & Sons, L.L.C. | 47 | $356 |
| Boehringer Ingelheim | 12 | $303 |
| Novo Nordisk | 10 | $278 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $210 |
| Kiniksa Pharmaceuticals International, PLC | 9 | $175 |
| Johnson & Johnson | 7 | $115 |
| Irhythm Technologies, Inc. | 2 | $103 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $82 |
| Lantheus Medical Imaging, Inc. | 3 | $40 |
| AstraZeneca | 2 | $33 |
| Lilly USA, LLC | 1 | $32 |
| Medtronic | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Teleflex LLC | 1 | $17 |
| Terumo Medical Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$9,027
- NEXLETOL$9,027
- Cleerly Ischemia$444
- Cleerly Labs$444
- WATCHMAN Access System$294
- FFRct$259
- JARDIANCE$107
How this compares
$14,057 in reported general payments places this provider in the 85th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 242 | $275,241 |
| Repatha SureclickEvolocumab | 94 | $80,692 |
| XareltoRivaroxaban | 72 | $72,923 |
| EntrestoSacubitril/Valsartan | 18 | $24,577 |
| JardianceEmpagliflozin | 17 | $17,919 |
| Ezetimibe | 129 | $5,349 |
| Nebivolol Hcl | 52 | $5,277 |
| Flecainide Acetate | 84 | $4,648 |
| Metoprolol Succinate | 300 | $4,239 |
| Ranolazine ErRanolazine | 29 | $3,803 |
| Rosuvastatin Calcium | 221 | $3,258 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 36 | $2,009 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 60 | $1,992 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 35 | $1,645 |
| Olmesartan Medoxomil | 67 | $1,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $115 | $72,92372 claims |
| NovartisEntresto | $602 | $24,57718 claims |
| Boehringer IngelheimJardiance | $303 | $17,91917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Nashville
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- George CrossleyNashville$197K
- Joel PharesNashville$171K
- Arvindh KanagasundramNashville$161K
- Jessica HustonNashville$109K
- Joshua BeckmanNashville$106K
- Travis RichardsonNashville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.